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Transverse aortic constriction 
induces gut barrier alterations, 
microbiota remodeling 
and systemic inflammation
Nicola Boccella1,9, Roberta Paolillo1,9, Lorena Coretti2,3,4,5,9, Stefania D’Apice1,9, 
Adriano Lama3,5, Giuseppe Giugliano1, Gabriele Giacomo Schiattarella1, Mariella Cuomo6, 
Ilaria d’Aquino7, Gina Cavaliere8, Orlando Paciello7,5, Maria Pina Mollica5,8, 
Giuseppina Mattace Raso3,5, Giovanni Esposito1, Francesca Lembo3,5,9* & Cinzia Perrino1,9* 
Accumulating evidence suggests that modifications of gut function and microbiota composition 
might play a pivotal role in the pathophysiology of several cardiovascular diseases, including heart 
failure (HF). In this study we systematically analysed gut microbiota composition, intestinal barrier 
integrity, intestinal and serum cytokines and serum endotoxin levels in C57BL/6 mice undergoing 
pressure overload by transverse aortic constriction (TAC) for 1 and 4 weeks. Compared to sham-
operated animals, TAC induced prompt and strong weakening of intestinal barrier integrity, long-
lasting decrease of colon anti-inflammatory cytokine levels, significant increases of serum levels of 
bacterial lipopolysaccharide and proinflammatory cytokines. TAC also exerted effects on microbiota 
composition, inducing significant differences in bacterial genera inside Actinobacteria, Firmicutes, 
Proteobacteria and TM7 phyla as shown by 16S rDNA sequencing of fecal samples from TAC or sham 
mice. These results suggest that gut modifications represent an important element to be considered 
in the development and progression of cardiac dysfunction in response to TAC and support this animal 
model as a valuable tool to establish the role and mechanisms of gut-heart crosstalk in HF. Evidence 
arising in this field might identify new treatment options targeting gut integrity and microbiota 
components to face adverse cardiac events.
Mammalian gut microbiota is composed by a diverse selection of microorganisms colonizing the gastroin-
testinal tract, generating a complex ecosystem with remarkable effects on nutrition, gut epithelial cell health, 
immunity, and  inflammation1. Different variables can affect microbiota composition, including genetics, age, 
diet, environmental factors and several human  diseases2,3. Interestingly, various experimental strategies have 
been described to modulate gut microbiota composition, including administration of antibiotics, probiotics, 
prebiotics, postbiotics, and fecal microbiota transplantation, associated to temporary or prolonged restoration 
of gut function, microbiota composition and immune  response4.
Several cardiovascular diseases (CVD) have been commonly associated with remarkable changes in gut bar-
rier function and microbiota composition through different, still largely undefined mechanisms, presumably 
acting at multiple  levels1,5. A mutual gut-heart crosstalk has been recently proposed in heart failure (HF), even 
if messengers and underlying mechanisms are still not entirely  defined6. Reduced cardiac output and peripheral 
vasoconstriction in HF can induce intestinal hypoperfusion, disrupt intestinal barrier function, promote systemic 
inflammation and affect gut microbiota  composition6–8. The potential roles of specific bacteria in the pathogenesis 
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of cardiometabolic disorders and their therapeutic implications are now starting to be  elucidated9–11. In addition, 
gut microbiota-derived molecules, either structural components or bioactive products, can exert remote effects 
through the activation of different signaling pathways in  CVD7,12,13. In this context, despite species-specific 
limitations, experimental systems including animal models are crucial to test for causal connections and provide 
novel insight into host–microbiota interactions modeling human health and diseases.
The murine model of transverse aortic constriction (TAC) is one of the most well-established and widely used 
preclinical models of pressure overload-induced cardiac hypertrophy and  failure14–16. It has been recently dem-
onstrated that choline diet and its gut microbe-derived metabolite Trimethylamine N-Oxide (TMAO) exacerbate 
TAC-induced HF, while nonlethal inhibition of TMAO production improves cardiac function and remodeling 
after TAC, clearly indicating that gut microbiota can affect cardiac function and remodeling induced by pressure 
 overload17,18. In the present study, we investigated the effects of TAC on intestinal barrier integrity, intestinal 
and serum cytokines, serum endotoxin levels and gut microbiota composition in C57BL/6 mice. Our results 
suggest that gut modifications might represent an important variable in the development and progression of 
cardiac dysfunction in response to TAC, and support this murine model as a valuable tool to establish the role 
and mechanisms of gut-heart crosstalk in HF.
Results
Intestinal permeability upon TAC leads to systemic LPS translocation and inflammation. As 
expected, TAC induced left ventricular hypertrophy and systolic dysfunction (left ventricle weight/body weight 
ratio: sham 1w = 3.5 ± 0.1, TAC 1w = 5.4 ± 0.5*, sham 4w = 3.4 ± 0.1, TAC 4w = 5.2 ± 0.4*; % fractional shorten-
ing: sham 1w = 59.1 ± 0.5, TAC 1w = 51.8 ± 0.9, sham 4w = 59.8 ± 0.3, TAC 4w = 46.2 ± 1.9*; *p < 0.01 vs. sham, 
Table 1). Immediately after TAC, abdominal aortic blood flow was significantly reduced in TAC mice compared 
to sham, resulting in intestinal hypoperfusion (Fig. 1A). Consistently, colon HIF 1-α levels were significantly 
increased after TAC 1w, and recovered in TAC 4w mice (Supplementary Fig. 1). Decreased intestinal perfusion 
in TAC 1w mice was associated to a prompt and strong weakening of intestinal barrier, as shown by reduced 
mRNA expression of Ocln and Tjp1 (Fig. 1B,C; see Supplementary Fig. 2 for pre-surgery values), and reduced 
immunostaining of zonula occludens-1 (zo-1) after 1w of pressure overload (Fig. 1D).
To determine the effects of TAC on gut barrier function, we analyzed circulating levels of FITC-dextran 
D4000 at different time intervals after oral administration by gavage in sham 1w and TAC 1w mice. In TAC 1w 
mice, circulating levels of FITC-dextran significantly increased 1 h after oral gavage, and thereafter decreased. 
In contrast, time-course of FITC-dextran circulating levels was delayed in sham 1w mice compared to TAC 1w, 
reaching peak concentration 2 h after oral administration, and decreasing thereafter (Fig. 1E). Gut barrier func-
tion was still functionally impaired in TAC 4w mice, as shown by differences in circulating levels of FITC-dextran 
between TAC 4w and sham 4w mice 1 h after gavage (Fig. 1F).
Colon expression levels of anti-inflammatory cytokine interleukin-10 (IL-10) were significantly reduced 
in TAC 1 w and TAC 4w colon samples compared to respective sham (Fig. 2A; see Supplementary Fig. 2 for 
pre-surgery values). These changes were associated to the histological evidence of remarkable inflammatory 
infiltrate in murine colon samples from TAC 1w mice (Fig. 2B). Consistent with these results, serum levels of 
Table 1.  Cardiac morphometry and echocardiography of mice from the different groups. Data are presented 
as mean ± SEM. An unpaired Student’s t-test was performed for each pair of four groups and subsequent 
multiple comparisons were made with use of the Tukey method. A p value < 0.05 was considered significant 
(*p < 0.05 vs. correspondent sham; #p < 0.05 vs. correspondent TAC 1w). BW Body weight, LVW left ventricle 
weight, HW heart weight, LVEDd left ventricular end-diastolic diameter, LVESd left ventricular end-systolic 
diameter, IVSd interventricular septum end-diastolic diameter, PWd posterior wall end-diastolic diameter, FS 
fractional shortening, EF ejection fraction, HR heart rate.
Morphometry
Sham 1w TAC 1w Sham 4w TAC 4w
(n = 4) (n = 4) (n = 15) (n = 18)
BW, g 23.9 ± 0.6 23.7 ± 0.6 26.1 ± 0.7 24.9 ± 0.6
LVW, mg 80.2 ± 1.5 114.7 ± 8.1* 88.4 ± 3.3 149.0 ± 6.4*#
HW, mg 110.0 ± 2.7 150.1 ± 10.2* 124.1 ± 4.7 193.3 ± 8.4*#
LVW/BW, mg/g 3.5 ± 0.1 5.4 ± 0.5* 3.4 ± 0.1 5.2 ± 0.4*
HW/BW, mg/g 4.8 ± 0.1 7.0 ± 0.7* 4.8 ± 0.2 7.8 ± 0.3*
Echocardiography
Sham 1w TAC 1w Sham 4w TAC 4w
(n = 20) (n = 25) (n = 15) (n = 18)
LVEDd, mm 3.3 ± 0.1 3.2 ± 0.05 3.4 ± 0.1 3.3 ± 0.1
LVESd, mm 1.4 ± 0.1 1.5 ± 0.04* 1.4 ± 0.1 1.8 ± 0.1*
IVSd, mm 0.9 ± 0.1 1.0 ± 0.02* 0.9 ± 0.1 1.2 ± 0.1*#
PWd, mm 0.9 ± 0.1 1.1 ± 0.04* 0.9 ± 0.1 1.3 ± 0.04*#
FS, % 59.1 ± 0.5 51.8 ± 0.9* 59.8 ± 0.3 46.2 ± 1.9*
EF, % 89.7 ± 0.4 83.6 ± 0.9* 90.0 ± 0.2 77.8 ± 2.6*#
HR, bpm 652 ± 8.4 635 ± 11 617 ± 14 655 ± 9.8
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Figure 1.  Effects of TAC or sham surgery on intestinal barrier integrity. (A) Abdominal aortic blood flow 
(cm/s) was evaluated at 1, 3, 7 and 28 days after surgical procedure in sham and TAC mice by Pulsed Wave 
Doppler (sham n = 6; TAC n = 10). (B,C) mRNA expression levels of occludin (Ocln, B) and tight junction 
protein ZO-1 (Tjp1, C) in colon samples from sham or TAC mice (sham: n = 3–4; TAC: n = 3–6). (D) 
Representative images of immunohistochemical analysis of tight junction protein ZO-1 in colon samples from 
the different groups of mice (sham 1w: n = 6; sham 4w: n = 5; TAC 1w: n = 4; TAC 4w: n = 6). ZO-1 positive 
cells were stained in brown; bigger brown and deeper color represent higher ZO-1 protein levels. Pictures are 
shown at 20 × and 40 × magnification. (E) Plasma levels of FITC-dextran 4000 at 15 min, 1, 2, 4 h after gavage 
in sham 1w and TAC 1w mice (sham 1w: n = 14; TAC 1w: n = 12). (F) Plasma levels of FITC-dextran 4000 1 h 
after gavage in sham 4w and TAC 4w (sham 4w: n = 4; TAC 4w: n = 4). Results are presented as mean ± SEM. 
Statistical significances were assessed using one-way ANOVA followed by Newman-Keuls multiple comparison 
post-hoc test (A) or Tukey’s comparison test as appropriate (B–F).
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lipopolysaccharide (LPS) and proinflammatory cytokines tumor necrosis factor-α (TNF-α) and interleukin-1 
(IL-1), were rapidly and persistently enhanced after TAC surgery (Fig. 2C), while circulating levels of IL-10 were 
reduced in TAC mice (Fig. 2C–F).
TAC impacts on fecal microbiota composition. Gut barrier integrity is closely linked to gut microbiota 
composition, and they can be reciprocally affected, especially in response to external pathological causes. Differ-
ences in fecal microbiota composition among sham and TAC mice were determined by 16S rDNA sequencing 
and a Good’s coverage index > 99% was obtained at the rarefaction point of 26,396 reads/sample. Comparison 
of fecal gut microbiota communities among groups revealed significant changes of bacterial genera inside Act-
inobacteria, Firmicutes, Proteobacteria and TM7 phyla. Specifically, intergroup differences at genus and species 
levels were analyzed by the linear discriminant analysis (LDA) effect size (LEfSe), identifying the genera Bifido-
bacterium, Lactobacillus, Turicibacter, unclassified genus (u.g.) of RF32 and u.g. of F16 as characteristic of TAC 
mice, whereas the genus Oscillospira was significantly less abundant in TAC mice compared to sham at specific 
time windows (Fig. 3A).
SPINGO high-resolution approach was used to obtain bacterial species assignment of key genera with sig-
nificant differences among groups (Fig. 3B). After TAC, a significant increase in OTUs resembling Bifidobac-
terium pseudolongum, Turicibacter sanguinis, Lactobacillus frumenti, and an unclassified species belonging to 
Proteobacteria phylum (order RF32) was detected, along with decrease of species within Oscillospira genus 
(Pseudoflavonifractor capillosus and Flavonifractor plautii, Fig. 3B).
In order to predict functional effects of gut microbiota alterations induced by TAC, we performed a Phy-
















































































































Figure 2.  Effects of TAC or sham surgery on inflammation. (A) mRNA expression levels of Interleukin-10 
(Il10) in colon samples (sham: n = 3–4; TAC: n = 3–6). (B) Representative hematoxylin and eosin–stained 
sections from colon tissues of mice at original magnifications ×20 and ×40. Histological evaluation of 
inflammatory cells infiltration was scored along the entire colon length, inspecting the colon mucosa, 
submucosa and transmural areas considering the following parameters: (a) severity of inflammatory cell 
infiltration (sham 1w = 0.83 ± 0.16, sham 4w = 1.40 ± 0.24, TAC 1w = 2.25 ± 0.25, TAC 4w = 1.83 ± 0.31); (b) 
extent of the inflammation as expansion of leukocyte infiltration (sham 1w = 1.17 ± 0.31, sham 4w = 1.20 ± 20, 
TAC 1w = 2 ± 0, TAC 4w = 1.50 ± 0.22); and (c) presence of fibrosis (sham 1w = 0 ± 0, sham 4w = 0 ± 0, TAC 
1w = 0.25 ± 0.25, TAC 4w = 0.33 ± 0.21). For details on the histological scoring system please see Materials and 
Methods section. Data reported are mean ± SEM (sham 1w: n = 6; sham 4w: n = 5; TAC 1w: n = 4; TAC 4w: n = 6). 
Serum levels of (C) lipopolysaccharide (LPS), (D) tumor necrosis factor-α (TNF-α), (E) interleukin-1 (IL-1) 
and (F) IL-10 in all experimental groups (sham: n = 4–8; TAC: n = 4–9). Results are presented as mean ± SEM. 
Statistical significances were assessed using one-way ANOVA followed by Newman–Keuls multiple comparison 
post-hoc test (A) or Tukey’s comparison test as appropriate (B–F).
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analysis revealed a significant increase in pathways inducing L-lactate dehydrogenase after 1w TAC (pre-surgery: 
2,445.6 ± 272.9; sham 1w: 2,038.4 ± 323.9; TAC 1w: 3,074 ± 331.6; p < 0.05 for sham 1w vs. TAC 1w according to 
two-tailed nonparametric Kruskal–Wallis test). Conversely, a trend to decrease of KEGG (Kyoto Encyclopedia 
of Genes and Genomes) functions involved in butyrate production (butyryl-CoA dehydrogenase, phosphate 
butyryltransferase, butyrate kinase) was observed after 4w TAC (data not shown). Collectively, these data indicate 
that a significant remodeling of specific bacterial species abundance within identified key genera occurs soon after 
TAC, identifying a clear effect of the surgery on microbiota profiles and, possibly, on microbiota functionality.
Discussion
In the present study we demonstrate that the murine model of TAC induces prompt and strong weakening 
of intestinal barrier integrity, decrease of colon anti-inflammatory cytokine levels, increase of serum levels of 
LPS and proinflammatory cytokines, and significant differences in fecal bacterial genera inside Actinobacteria, 
Firmicutes, Proteobacteria and TM7 phyla. Our findings clearly support this murine model as a valuable tool to 
establish the importance of gut barrier function and microbiota composition in HF.
Several studies have demonstrated that a decrease in gut perfusion structurally and functionally affects intes-
tinal barrier  integrity19. In patients with HF, both alteration of villi shape in intestinal mucosa resulting in intra-
mucosal  acidosis20,21 and intestinal wall thickness with edema have been  demonstrated22. Moreover, even if with 
multiple discrepancies, alterations in gut microbial communities have been reported in patients with  HF22–29. 
Our experiments showed that TAC was associated with a prompt reduction in abdominal aortic blood flow and 
intestinal hypoperfusion, accompanied by a rapid impairing of gut barrier structure as demonstrated by reduction 
of zonula occludens-1 and occludin levels and increased FITC-dextran translocation across intestinal epithelium 
into blood. Moreover, we concurrently found a significant increase of LPS and proinflammatory cytokines in 
systemic blood circulation of TAC mice compared to sham. Of note, together with remarkable inflammatory 
infiltrate persistence and high levels of inflammatory markers, gut barrier was still functionally compromised 
in TAC 4w mice, as revealed by FITC-dextran in vivo permeability assay, despite a recovery of tight junctions 
mRNA and proteins levels at this time point. We cannot exclude that at later time points gut barrier function 
could be restored.
These dramatic alterations of gut barrier due to hypoperfusion induced by TAC were associated with remark-
able changes in gut microbiota composition. Based on LEfSE results, taxa correlated to dysbiosis and colonic 
inflammation, such as F16, significantly increased after TAC 30–32. Furthermore, we identified unclassified genus 
of RF32 (Proteobacteria phylum) as a potential microbial biomarker and source of LPS in TAC operated mice, 
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Figure 3.  Gut microbiota composition after sham or TAC surgery in mice. Gut microbiota differences based on 
16S rDNA sequencing at genus (A) and species (B) taxonomic levels were identified using linear discriminant 
analysis (LDA) combined with effect size (LEfSe) algorithm. In each panel, LDA scores (left) and relative 
abundance (right) of key phylotypes discriminating sham and TAC bacterial communities are reported (sham 
n = 8; TAC n = 9). Statistical significances were assessed using LEfSe analysis with alpha values of 0.05 for both 
Kruskal–Wallis and pairwise Wilcoxon tests and a cutoff value of LDA score (log10) above 2.0 (*p < 0.05 and 
**p < 0.01 vs. correspondent sham).
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possibly contributing to colonic inflammation. Moreover, in TAC 4w mice gut microbiota was characterized by 
an increase in genera Turicibacter and Lactobacillus. The increase of these lactate-producing bacteria (namely 
T. sanguinis and L. frumenti, according to species-level SPINGO classification) concurred with the depletion of 
butyrate-producing bacteria (genus Oscillospira, taxonomically classified as P. capillosus and F. plautii species after 
SPINGO procedure) in TAC mice, and these results were also corroborated by PICRUST analysis. Recent studies 
have implicated increases in genus Lactobacillus in pathophysiology of cardiovascular diseases, even if conflicting 
results have been reported in HF. Increases in lactate-producing Lactobacillus have been demonstrated in elderly 
patients with HF and in animal models of  hypertension24,33. Consistently, ST-segment elevation myocardial 
infarction (STEMI) patients were characterized by increased circulating levels of intestinal Lactobacilli, associated 
with systemic inflammation and adverse cardiovascular  events33. On the contrary, ferulic acid administration, 
which improves cardiac function in TAC mice, has been shown to increase intestinal Lactobacillus34. Moreover, 
a reduction of Lactobacillus has been reported in gut microbiota of rats with isoproterenol-induced  HF35. Thus, 
further investigations will be necessary to clarify the role of Lactobacillus phylotypes in the pathophysiology of 
HF, ideally with species-level approaches.
A significant depletion of genus Oscillospira, an under-investigated bacterium usually considered a biomarker 
of intestinal and host wellness, was also identified in TAC mice. Presence of this bacterium has been associated 
to leanness, resulting depleted in obese patients and reduced in diseases that involve inflammation, and these 
associations have been inferred to the putative capacity of Oscillospira species to produce  butyrate36. Butyrate-
producing bacteria are considered relevant colonizers of the gastrointestinal tract with known anti-inflammatory 
effects and a prominent role in maintaining intestinal barrier  integrity37,38. Consistent with our findings in TAC 
mice, butyrate-producing bacteria such as Faecalibacterium and Blautia genera, were also depleted in other 
animal models of  hypertension39 and in studies involving patients with  HF24–26. Thus, the unbalance between 
butyrate and lactate producing bacteria might represent a possible mark of gut microbiota adaptations to the new 
environment induced by intestinal hypoperfusion in presence of HF. Overall, we propose that gut hypoperfu-
sion induced by TAC structurally and functionally affects intestinal barrier with an effect on the balance of gut 
microbiota composition. TAC-induced gut dysbiosis and enhanced gut permeability may in turn affect systemic 
inflammation possibly contributing to cardiac dysfunction.
Conclusions
Alterations of gut structure/function and dysbiosis may represent important elements to be considered in the 
development or progression of cardiac dysfunction in response to pressure overload induced by TAC. Whether 
restoration of gut function and microbiota composition might exert a beneficial effect on cardiac remodeling 
and dysfunction is still unknown and will require further investigations. However, our findings clearly support 
the murine model of TAC as a valuable tool to establish the importance of gut barrier function and microbiota 
composition in HF, suggesting novel important avenues of research in this field, including administration of 
single or defined cocktails of bacterial species to counteract alterations in gut barrier integrity during HF.
Methods
Ethics statement. All experiments and methods were performed in accordance with relevant guidelines 
and regulations. All experiments involving animals in this study were conform to the Guide for the Care and 
Use of Laboratory Animals published by the US National Institutes of Health. All in vivo experimental protocols 
were approved by the animal welfare regulation of University of Naples “Federico II”, Italy, and by the Superior 
Institute of Health, Italy. Animal studies were carried out in compliance with the ARRIVE (Animal Research: 
Reporting of In Vivo Experiments) guidelines.
Experimental animals. C57BL/6 (Charles River Laboratories) mice of either sex (8-week-old) were 
included in the study and were maintained under identical conditions of temperature (21 ± 1  °C), humidity 
(60 ± 5%), and light/dark cycle of 12 h and had free access to water and normal mouse chow diet. One month 
before either sham or TAC surgery, mice generated by different mothers were placed in cages (groups of 2–3 
mice/cage). After surgery, mice were kept in single cages until study termination.
Mouse model of pressure overload-induced cardiac hypertrophy and heart failure. Pressure 
overload was induced in adult C57BL/6 mice by TAC as previously  described40. Mice were anesthetized by 
administration of 5% sevoflurane and 95%  O2 and a suture was surgically placed across the aortic arch between 
the left common carotid artery and the innominate artery. Another group of animals underwent a left thora-
cotomy without aortic constriction (sham). Mice from sham and TAC groups were sacrificed 1 week (1w) and 
four weeks (4w) after surgery to perform molecular analyses. Only TAC animals with systolic pressure gradi-
ents > 40 mmHg measured by Doppler echocardiography were included in the study (see below).
Cardiovascular ultrasound and Doppler. Cardiac function was non-invasively monitored by transtho-
racic echocardiography, using the Vevo 2100 high-resolution imaging system (Visual-Sonics, Toronto, ON, 
Canada) before, 1w and 4w after surgery as previously  described41. Briefly, mice were anesthetized by an intra-
peritoneal injection of 0.1 ml/kg of mixture of 50% tiletamine and 50% zolazepam (Zoletil 100) and echocardi-
ography was performed. Echocardiographic measurements were obtained from grayscale M-mode images at the 
mid-papillary level in the parasternal short-axis. Conventional measurements of the left ventricle (LV) included: 
left ventricular end-diastolic diameter (LVEDd), left ventricular end-systolic diameter (LVESd), interventricular 
septum end-diastolic diameter (IVSd), posterior wall end-diastolic diameter (PWd), heart rate (HR), % frac-
tional shortening (FS %) and % ejection fraction (EF%). Pressure gradients across transverse aorta induced by 
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TAC were evaluated using pulsed wave (PW) Doppler analysis 1w and 4w after surgery. Abdominal aortic flow 
was non-invasively estimated by PW Doppler before, 1, 3, 7, and 28 days after TAC or sham surgery.
Microbiota sequencing and data analysis. To study fecal microbiota composition of sham and TAC 
mice, 16S rRNA gene sequences were obtained and pre-processed as previously  described42. Resulting data were 
analyzed using Quantitative Insights Into Microbial Ecology (QIIME, version 1.9.1)43. Microbiota reads were 
collapsed into operational taxonomic units (OTUs) using a closed reference-based OTU picking method against 
Greengenes 16S gene database (GG, may 2013 version)44 at 97% of sequences similarity; picked OTUs were 
classified at different taxonomic levels with the GG database. Species classification was performed using SPe-
cies IdentificatioN of metaGenOmic amplicons program (SPINGO version 1.3) with default parameters on a 
representative sequence of each OTU according to Ribosomal Database Project taxonomy and a 80% minimum 
bootstrap  cutoff45. To avoid sample size biases in subsequent analyses, a sequence rarefaction procedure was 
applied using a depth of 26,396 sequences/sample. Species heterogeneity within each sample was assessed by 
employing two Alpha diversity metrics (the number Observed species and the Shannon entropy) and compared 
using a two-sample permutation t-test, using 999 Monte Carlo permutations to compute p-values. OTUs diver-
sity among microbial communities (beta diversity) was assessed by calculating unweighted and weighted Uni-
frac distances and compared by using ANOSIM method with 999 permutations. Statistical differences in OTUs 
frequencies among groups across different taxonomic levels were assessed with Linear Discriminant Analysis 
(LDA) combined with effect size (LEfSe; p < 0.05 by Kruskal–Wallis test, p < 0.05 by pairwise Wilcoxon test 
and logarithmic LDA score of 2.0)46. Normalized OTU table, corrected for multiple 16S rRNA gene copy num-
ber, was used for metagenomes prediction in  PICRUSt47. Kyoto encyclopedia of genes and genomes (KEGG) 
ortholog abundances of key functions involved in butyrate metabolism among groups were compared using 
two-tailed nonparametric Kruskal–Wallis test.
RNA extraction and real-time semi-quantitative PCR. Mice colons were dissected at 1w and 4w after 
sham and TAC procedures for mRNA expression  analysis42. Total RNA was extracted from colonic tissues by 
TRIzol Reagent (Bio-Rad Laboratories, Hercules, CA, USA), following the instructions of RNA extraction kit 
(NucleoSpin, MACHEREY–NAGEL GmbH & Co, Düren, Germany). cDNA was obtained using High-Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA) from 4 μg total RNA. PCRs were 
performed with a Bio-Rad CFX96 Connect Real-time PCR System instrument and software (Bio-Rad Laborato-
ries). The PCR conditions were 15 min at 95 °C followed by 40 cycles of two-step PCR denaturation at 94 °C for 
15 s, annealing extension at 55 °C for 30 s and extension at 72 °C for 30 s. Each sample contained 500 ng cDNA 
in 2X QuantiTect SYBRGreen PCR Master Mix and primers pairs to amplify interleukin-10 (Il10), zonuline-1 
(Tjp1), occludin (Ocln) (Qiagen, Hilden, Germany) in a final volume of 50 μl. The relative amount of each stud-
ied mRNA was normalized to GAPDH as housekeeping gene, and data were analysed according to the  2−ΔΔCT 
method.
Serum ELISA assay. Blood samples were collected at sacrifice. Levels of IL-10, interleukin-1α (IL-1α), 
interleukin-6 (IL-6) and tumor necrosis factor α (TNFα) were measured using available ELISA kits (Thermo 
Scientific, Rockford, IL RBMS627R and RBMS629R, Biovendor R and D, Brno, Czech Republic). Lipopolysac-
charide (LPS) levels were measured using the Limulus amebocyte lysate (LAL QCL-1000; Lonza Group Ltd., 
Basel, Switzerland), according to the manufacturer’s instructions.
In vivo intestinal permeability assay. This examination is based on the intestinal permeability to fluo-
rescein isothiocyanate-labeled dextran D4000 (FITC-dextran D4000) (Sigma-Aldrich, Milan, Italy) as previ-
ously  described42,48. After 12 h of food withdrawal, mice were orally administered with FITC-dextran D4000 
(50 mg/100 g body weight, 125 mg/ml). After 15 min, 1 h, 2 h and 4 h hours blood of all animals was collected 
by intracardiac puncture and centrifuged at 4 °C, 1200 rcf, for 10 min. Then plasma FITC-dextran concentration 
was determined (excitation, 485 nm; emission, 535 nm; HTS-7000 Plus-plate-reader; Perkin Elmer, Wellesley, 
MA, USA), using a standard curve generated by serial dilution of the tracer.
Histological analysis. Colon samples from sham and TAC mice were collected, washed and placed in 10% 
neutral buffered formalin and embedded in paraffin wax; sections were cut and stained with haematoxylin and 
eosin (H&E; Carlo Erba, Italy). Sections were examined and scored using a 0-to-4 scale as previously  described42. 
Histological scoring system was as follows: (a) the severity of inflammatory cell infiltration was evaluated by 
percentage of leukocyte density in lamina propria area and estimated in a high-power field (HPF) representative 
of the section (0 for no signs of inflammation, 1 for minimal < 10%, 2 for mild 10–25%, 3 for moderate 26–50%, 
4 for marked > 51% with dense infiltrate); (b) the extent of the inflammation was estimated as expansion of leu-
kocyte infiltration (0 for none, 1 for mucosal, 2 for mucosal and submucosal and 3 for mucosal, submucosal and 
transmural level); (c) the presence of fibrosis (0 for none, 1 if present).
For immunohistochemistry, 4-µm-thick sections were processed with the MACH1 Universal HRP Polymer 
Detection Kit (Biocare Medical LLC, Concord, CA). Colon tissues were mounted on positively charged glass 
slides (Bio-Optica, Milan). Antigen retrieval pretreatments were performed using a heat-induced epitope retrieval 
(HIER) citrate buffer pH6.0 (Bio- Optica, Milan, Italy) for 20 min at 98 °C; peroxide block was applied for 15 min 
at room temperature, and then the sections were incubated for 30 min with background sniper (Biocare Medi-
cal LLC). The primary antibodies were diluted in phosphate-buffered saline (PBS) and incubated overnight at 
4 °C. Horseradish peroxidase (HRP) polymer was added for 30 min at room temperature. After every step, the 
sections were washed in 0.01 M PBS (pH 7.2–7.4). The reaction was revealed by using 3,30-diaminobenzidine 
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(DAB) chromogen diluted in DAB substrate buffer. Finally, sections were counterstained in Carazzi’s haema-
toxylin (code n. 05-06012/L, Bio-Optica, Milan, Italy). Primary antibodies included rabbit monoclonal to ZO-1 
(61-7300 ThermoFisher Scientific, Waltham, MA) diluted 1:10049.
Protein extraction and immunoblotting. Colon samples were homogenized in a buffer containing 
150 mmol/L NaCl, 50 mmol/L Tris–HCl (pH 8.5), 2 mmol/L EDTA, 1% v/v NP-40, 0.5% w/v deoxycholate, 
10 mmol/L NaF, 10 mM sodium pyrophosphate, 2 mmol/L PMSF, 2 heart leupeptin, 2 heart aprotinin, pH 7.4, 
using the program Protein_1 on a GentleMACS tissue Dissociator (Miltenyi Biotec)50. Protein concentration in 
all lysates was measured by using a dye-binding protein assay kit (Bio-Rad) and a SmartSpec Plus spectropho-
tometer (Bio-Rad) reading at a wavelength of 595 nm. Immunoblotting was performed by using commercially 
available antibodies: anti-HIF-1α (mouse monoclonal, Novus Biologicals) and anti-tubulin (mouse monoclonal, 
Sigma-Aldrich). Secondary antibodies were purchased from Santa Cruz Biotechnology. Bands were visualized 
by enhanced chemiluminescence (ECL; Millipore Corporation) according to the manufacturer’s instructions, 
and were quantified by using densitometry (Chemidoc, Bio-Rad). Each experiment and densitometric quantifi-
cation was separately repeated at least three times.
Statistical analysis. All data presented are representative of three or more independent experiments and 
are expressed as mean ± SEM. All statistical analyses, with the exception of microbiota data processing, were 
conducted with Prism 8 statistical software; a minimum value of p < 0.05 was considered statistically signifi-
cant. Comparisons between two groups were performed using the unpaired Student’s t-test. For experiments 
including three or more experimental groups, comparisons were made by one-way analysis of variance or 2-way 
ANOVA. Correction for multiple comparisons was made using the Tukey’s multiple comparison test. For each 
experiment, the number of mice used was specified in the figure legends.
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